Preview Mode Links will not work in preview mode

Journal of Clinical Oncology recognizes that readers do not always have time to review an article in depth, and yet they still wish to understand how the results will influence their clinical practice or research. To address this need, we offer podcasts that will enhance the readership experience by presenting the key results of high-profile publications in a convenient audio format. Our podcasts are designed to place selected articles into a clinically useful perspective that is easy to listen to in the office or while on the road.

Life is busy, and it’s hard to get it all done during business hours! Journal of Clinical Oncology recognizes that you do not always have time to review an article in depth, and yet you wish to understand how the results will influence your clinical practice or research. JCO After Hours is a podcast intended to enhance the readership experience by presenting key results of high-profile publications in a convenient audio format, placing selected articles into a clinically useful perspective that you can listen to in the office or on the road.

Mar 28, 2011

By Mary Daly. Stage at diagnosis of breast cancer among women with BRCA1/2 mutations was available for women enrolled in a multi-modality screening protocol including breast MRI, and for women who were screened with routine mammography. There was a significant increase in early stage at diagnosis for women in the MRI...


Mar 24, 2011

By David Ryan. This JCO Podcast provides observations and commentary on the JCO article, "Clinical Significance of Circulating Tumor Cells Including Cancer Stem-like Cells in Peripheral Blood for Recurrence and Prognosis in Colorectal Cancer Patients with Dukes stage B and C" by authors Hisae Iinuma, et al.


Mar 17, 2011

By Reed Drews. This JCO Podcast provides observations and commentary on the JCO article, "Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis" by authors Animesh Pardanani, et al.


Mar 17, 2011

By Lisa Carey. The randomized Phase III trial, Ribbon-1, was designed to examine whether the benefit of bevacizumab added to chemotherapy in metastatic breast cancer was specific to the taxanes or if the benefit could accrue regardless of the chemotherapy backbone. PFS was improved with the addition of bevacizumab to...


Mar 17, 2011

By David Avigan. This podcast describes a phase III randomized study comparing the efficacy and toxicity of Denosumab with Zolendronic Acid for the prevention of skeletal complications in patients with malignancy.